中图分类号：
R767
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2016[J].CA Cancer J Clin,2016,66(1):7-30.
[2] ALMADORI G,BUSSU F,CADONI G,et al.Molecular markers in laryngeal squamous cell carcinoma:Towards an integrated clinicobiological approach[J].Eur J Cancer,2005,41(5):683-693.
[3] ZHANG SS,XIA QM,ZHENG RS,et al.Laryngeal cancer incidence and mortality in China,2010[J].J Cancer Res Ther,2015,11(Suppl 2):C143-C148.
[4] DE STEFANI E,CORREA P,OREGGIA F,et al.Risk factors for laryngeal cancer[J].Cancer,1987,60(12):3087-3091.
[5] STEUER CE,EL-DEIRYM,PARKS JR,et al.An update on larynx.cancer[J].CA Cancer J Clin,2017,67(1):31-50.
[6] AWAD F,ASSRAWI E,LOUVRIER C,et al.Inflam-masome biology,molecular pathology and therapeutic implications[J].Pharmacol Ther,2018,187:133-149.
[7] ZITVOGEL L,KEPP O,GALLUZZI L,et al.Inflammasomes in carcinogenesis and anticancer immune responses[J].Nature Immunology,2012,13(4):343-351.
[8] DEVAIAH BN,SINGER DS.CⅡTA and its dual roles in MHC gene transcription[J].Front Immunol,2013,4(476):1-6.
[9] ECONOMOPOULOU P,AGELAKI S,PERISANIDIS C,et al.The promise of immunotherapy in head and neck squamous cell carcinoma[J].Annals Oncol,2016,27(9):1675-1685.
[10] HE Y,ROZEBOOM L,RIVARD CJ,et al.MHC class Ⅱ expression in lung cancer[J].Lung Cancer,2017,112:75-80.
[11] XIE XW,MEI MH,LIAO WJ,et al.Expression of CⅡTA-related MHCⅡ molecules in tumors linked to prognosis in hepatocellular carcinoma[J].Int J Oncol,2009,34(3):681-688.
[12] FORERO A,LI Y,CHEN D,et al.Expression of the MHC Class Ⅱ pathway in triple-negative breast cancer tumor cells is associated with a good prognosis and infiltrating lymphocytes[J].Cancer Immunol Res,2016,4(5):390-399.
[13] TANG Z,LI C,KANG B,et al.GEPIA:a web server for cancer and normal gene expression profiling and interactive analyses[J].Nucleic Acids Res,2017,45(W1):W98-W102.
[14] HANNA S,ETZIONI A.MHC class Ⅰ and Ⅱ deficiencies[J].J Allergy Clin Immunol,2014,134(2):269-275.
[15] VORA AR,RODGERS S,PARKER AJ,et al.An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma[J].Br J Cancer,1997,76(7):836-844.
[16] MOTTOK A,WOOLCOCK B,CHAN FC,et al.Genomic alterations in CⅡTA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class Ⅱ Eexpression[J].Cell Reports,2015,13(7):1418-1431.
[17] YAZAWA T,ITO T,KAMMA H,et al.Complicated Mechanisms of Class Ⅱ transactivator transcription deficiency in small cell lung cancer and neuroblastoma[J].Am J Pathol,2002,161(1):291-300.
[18] TAN W,HILDEBRANDT MA,PU X,et al.Role of inflammatory related gene expression in clear cell renal cell carcinoma development and clinical outcomes[J].J Urol,2011,186(5):2071-2077.
[19] MATHER Q,PRIEGO J,WARD K,et al.A novel protein expression.signature differentiates benign lipomas from well-differentiated liposarcomas[J].Mol Clin Oncol,2017,7(3):315-321.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家自然科学基金（81772878，30801283，30972691）；上海市科委青年科技启明星项目（09QA1401000，10QA1405900，14411961900）；上海市卫生系统优秀青年人才培养计划（XYQ2011055，XYQ2011015）；上海市科委生物医药处西医类引导重点项目（14411961900）；国家重点研发计划项目（2017YFA0104500）
{{custom_fund}}
PDF(5339 KB)
